GSC
CORT icon

Ground Swell Capital’s Corcept Therapeutics CORT Stock Holding History

Ground Swell Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,885
Closed -$240K – 131
2025
Q4 		$240K Buy
+6,885
New +$541K 0.49% 31
2022
Q3 		– Sell
-13,545
Closed -$322K – 122
2022
Q2 		$322K Buy
+13,545
New +$295K 0.59% 54
2014
Q3 		– Sell
-2,079
Closed -$6K – 2442
2014
Q2 		$6K Buy
+2,079
New +$6.14K 0.01% 969

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Ground Swell Capital's CORT Position: Q1 2026 in Review

Ground Swell Capital sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 6,885 shares — an estimated $240K sold.

Ground Swell Capital first reported a position in CORT in Q2 2014 and held it in 3 quarters. The position peaked at $322K in Q2 2022. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Ground Swell Capital reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ground Swell Capital sold 6,885 Corcept Therapeutics shares in Q1 2026, an estimated $240K.
  • Ground Swell Capital first reported a position in Corcept Therapeutics in Q2 2014 and held it in 3 quarters.
  • Ground Swell Capital's Corcept Therapeutics position peaked at $322K in Q2 2022.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Ground Swell Capital's 13F filing for Q1 2026, filed 21 Apr 2026.